Roche Diagnostics India announced the company has launched its first high throughput, fully integrated laboratory automation system Cobas 8800 and Cobas 6800 in India to aid with SARS CoV-2 diagnostic testing.
Cobas 8800 instrument was launched at the National Institute of Cholera and Enteric Diseases, Kolkata (ICMR-NICED) and Cobas 6800 was launched at National Institute for Research in Reproductive Health, Mumbai (ICMR- NIRRH).
Operating on the real-time reverse transcription-polymerase chain reaction (RT-PCR) platform, SARS-CoV-2 diagnostic tests on the instrument detects the RNA of the virus through a simple test performed by a healthcare provider using nasopharyngeal and oropharyngeal swab samples.
The company said that the Cobas 6800/8800 systems provide test results in three and half hours and offer improved operating efficiency, flexibility and fastest time-to-results.
The fully automated Cobas 6800/8800 systems do not require sorting or batching of samples, reagent preparation, or manual set-up of runs. The system helps reduce the turnaround time, maintaining testing efficiency and improved productivity of lab personnel on account of automation.
The high throughput testing provides up to 96 results in about three hours using cobas 8800. A total of 384 results can be provided through the cobas 6800 System and 960 results for the cobas 8800 System in 8 hours. The molecular tests can be run simultaneously with other diagnostic assays provided by Roche Diagnostics, including HIV and Hepatitis.
“With Cobas 6800 machine the COVID -19 testing capacity will go up to around 1000 samples per day, stated Dr Smita Mahale, Director, National Institute For Research in Reproductive Health, Mumbai in a press statement.